{"schema_version":"secwatch.filing_event.v1","accession":"0001625297-25-000032","form_type":"8-K","ticker":"INDV","cik":"0001625297","company_name":"Indivior Pharmaceuticals, Inc.","filed_at":"2025-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.104915+00:00","generated_at":"2026-05-22T04:36:32.458892+00:00","sec_items":["5.02","1.01","5.03","5.07","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.7,"confidence":"high","headline":"Indivior CEO transition finalized as Ciaffoni takes over; articles amended for Nasdaq primary listing","bullets":["Joe Ciaffoni commenced as CEO on May 8, 2025, following shareholder approval of remuneration policy.","Mark Crossley stepped down as CEO and director; separation terms previously filed.","Shareholders approved new articles of association with changes, including annual director re-elections and shift to Nasdaq as primary exchange.","All 19 resolutions at the 2025 AGM passed by poll; voter turnout ~64%.","New articles remove LSE references and adjust meetings/proxy rules; full text filed as Exhibit 3.1."],"urls":{"canonical":"https://secwatch.observer/filing/0001625297-25-000032","json":"https://secwatch.observer/filing/0001625297-25-000032.json","markdown":"https://secwatch.observer/filing/0001625297-25-000032.md","text":"https://secwatch.observer/filing/0001625297-25-000032.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1625297/000162529725000032/0001625297-25-000032-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1625297/000162529725000032/indv-20250508.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T04:36:32.458892+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ce85a30096","claim":"Mark Crossley departed as Chief Executive Officer at Indivior Pharmaceuticals, Inc..","evidence_excerpt":"Also, pursuant to his separation agreement, Mark Crossley stepped down as CEO of the Company and as a director.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1625297/000162529725000032/0001625297-25-000032-index.htm","confidence":0.95},{"claim_id":"fa9a64af69","claim":"Joe Ciaffoni was appointed as Chief Executive Officer at Indivior Pharmaceuticals, Inc..","evidence_excerpt":"Following shareholder approval of the Company’s Directors’ Remuneration Policy, the Company and Joe Ciaffoni agreed that his employment as CEO would commence on May 8, 2025.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1625297/000162529725000032/0001625297-25-000032-index.htm","confidence":0.95}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}